NRx Pharma narrows Q2 net loss to $7.9M; secures $10.8–16.3M convertible debt for NDAs

NRX Pharmaceuticals, Inc.

Q2 net loss $7.9M vs $8.7M YoY; six-month net loss $14.4M vs $19.8M.
Secured $10.8–16.3M convertible debt from Anson Funds; retired Streeterville debt at litigation discount.
Plans to file NDAs for NRX-100 (IV ketamine) and NRX-101 for bipolar depression in Q4 2024.
HOPE Therapeutics audit complete; spinout SEC filing planned this quarter.
Cash $1.9M at June 30; new funding expected to support filings and operations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.